Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning
- PMID: 17530007
- DOI: 10.1038/sj.bmt.1705701
Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning
Abstract
Reports on infectious complications following reduced intensity conditioning (RIC) before allogeneic stem cell transplantation (allo-SCT) are equivocal. This prospective follow-up study compared the impact of cytomegalovirus (CMV) infections following RIC with fludarabine, ATG and busulphan or conventional myeloablative conditioning (MAC). Forty-eight RIC and 59 MAC patients were enrolled. The occurrence and severity of CMV infections within 100 days following allo-SCT were assessed, using plasma CMV DNA load kinetics. CMV DNAemia was observed in 21 RIC (60%) and in 19 MAC (44%) patients at risk for CMV. The mean CMV DNAemia free survival time was comparable following RIC and MAC: 70 days (95% (confidence interval) CI: 59-80 days) and 77 days (95% CI: 68-86 days), respectively (P=0.24). Parameters indicative for the level of CMV reactivation, including the area under the curve of CMV DNA load over time as well as the onset, the peak values and duration of CMV infection episodes, the numbers and duration of CMV treatment episodes and recurrent infections, were not different in both groups. During follow-up, none of the patients developed CMV disease. RIC with fludarabine, ATG and busulphan demonstrated safety comparable to conventional MAC with regard to frequency and severity of CMV infections within 100 days following T cell-depleted allo-SCT.
Similar articles
-
Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation.Ann Hematol. 2003 Oct;82(10):621-7. doi: 10.1007/s00277-003-0706-1. Epub 2003 Aug 15. Ann Hematol. 2003. PMID: 12920570
-
Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients.Biol Blood Marrow Transplant. 2009 Dec;15(12):1587-95. doi: 10.1016/j.bbmt.2009.08.006. Epub 2009 Sep 30. Biol Blood Marrow Transplant. 2009. PMID: 19896083
-
Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia.Bone Marrow Transplant. 2003 Oct;32(7):695-701. doi: 10.1038/sj.bmt.1704164. Bone Marrow Transplant. 2003. PMID: 13130317 Clinical Trial.
-
Clinical aspects of CMV infection after stem cell transplantation.Hum Immunol. 2004 May;65(5):432-6. doi: 10.1016/j.humimm.2004.02.022. Hum Immunol. 2004. PMID: 15172442 Review.
-
Immune reconstitution after allogeneic stem cell transplantation with reduced-intensity conditioning regimens.Leukemia. 2007 Aug;21(8):1628-37. doi: 10.1038/sj.leu.2404681. Epub 2007 May 24. Leukemia. 2007. PMID: 17525730 Review.
Cited by
-
Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC study.Bone Marrow Transplant. 2021 Jun;56(6):1305-1315. doi: 10.1038/s41409-020-01178-6. Epub 2020 Dec 18. Bone Marrow Transplant. 2021. PMID: 33339900
-
The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients.Blood Adv. 2023 Mar 14;7(5):856-865. doi: 10.1182/bloodadvances.2022008667. Blood Adv. 2023. PMID: 36350752 Free PMC article.
-
Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion.Int J Hematol. 2010 Jun;91(5):877-85. doi: 10.1007/s12185-010-0597-6. Epub 2010 May 21. Int J Hematol. 2010. PMID: 20490728
-
Oral bacteria and yeasts in relationship to oral ulcerations in hematopoietic stem cell transplant recipients.Support Care Cancer. 2012 Dec;20(12):3231-40. doi: 10.1007/s00520-012-1463-2. Epub 2012 Apr 26. Support Care Cancer. 2012. PMID: 22531876 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical